Combination of cancer-specific prodrug nanoparticle with Bcl-2 inhibitor to overcome acquired drug resistance
出版年份 2020 全文链接
标题
Combination of cancer-specific prodrug nanoparticle with Bcl-2 inhibitor to overcome acquired drug resistance
作者
关键词
Cancer-specific prodrug nanoparticles, Bcl-2 inhibitor, Combination therapy, Inhibitor of drug resistance, Drug resistance
出版物
JOURNAL OF CONTROLLED RELEASE
Volume 330, Issue -, Pages 920-932
出版商
Elsevier BV
发表日期
2020-11-03
DOI
10.1016/j.jconrel.2020.10.065
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Macroporous organosilicon nanocomposites co-deliver Bcl2-converting peptide and chemotherapeutic agent for synergistic treatment against multidrug resistant cancer
- (2019) Jingjing Xie et al. CANCER LETTERS
- Modular Nanoparticulate Prodrug Design Enables Efficient Treatment of Solid Tumors Using Bioorthogonal Activation
- (2018) Miles A. Miller et al. ACS Nano
- Carrier-free nanoparticles of cathepsin B-cleavable peptide-conjugated doxorubicin prodrug for cancer targeting therapy
- (2018) Man Kyu Shim et al. JOURNAL OF CONTROLLED RELEASE
- Combination of nitric oxide and drug delivery systems: tools for overcoming drug resistance in chemotherapy
- (2017) Jihoon Kim et al. JOURNAL OF CONTROLLED RELEASE
- Monitoring doxorubicin cellular uptake and trafficking using in vitro Raman microspectroscopy: short and long time exposure effects on lung cancer cell lines
- (2016) Zeineb Farhane et al. ANALYTICAL AND BIOANALYTICAL CHEMISTRY
- Cathepsin B-Specific Metabolic Precursor for In Vivo Tumor-Specific Fluorescence Imaging
- (2016) Man Kyu Shim et al. ANGEWANDTE CHEMIE-INTERNATIONAL EDITION
- The BCL2 Family: Key Mediators of the Apoptotic Response to Targeted Anticancer Therapeutics
- (2015) A. N. Hata et al. Cancer Discovery
- Glycol chitosan nanoparticles as specialized cancer therapeutic vehicles: Sequential delivery of doxorubicin and Bcl-2 siRNA
- (2014) Hong Yeol Yoon et al. Scientific Reports
- Drug Resistance in Cancer: An Overview
- (2014) Genevieve Housman et al. Cancers
- Tumor-targeting multi-functional nanoparticles for theragnosis: New paradigm for cancer therapy
- (2012) Ju Hee Ryu et al. ADVANCED DRUG DELIVERY REVIEWS
- Nanotechnology applied to overcome tumor drug resistance
- (2012) Zibin Gao et al. JOURNAL OF CONTROLLED RELEASE
- Navitoclax (ABT-263) Reduces Bcl-xL-Mediated Chemoresistance in Ovarian Cancer Models
- (2012) M. Wong et al. MOLECULAR CANCER THERAPEUTICS
- Multicenter Phase II Trial of Temozolomide in Mycosis Fungoides/Sezary Syndrome: Correlation with O6-Methylguanine-DNA Methyltransferase and Mismatch Repair Proteins
- (2011) C. Querfeld et al. CLINICAL CANCER RESEARCH
- Substantial Susceptibility of Chronic Lymphocytic Leukemia to BCL2 Inhibition: Results of a Phase I Study of Navitoclax in Patients With Relapsed or Refractory Disease
- (2011) Andrew W. Roberts et al. JOURNAL OF CLINICAL ONCOLOGY
- Reversal of doxorubicin-resistance by multifunctional nanoparticles in MCF-7/ADR cells
- (2011) Ming-Jium Shieh et al. JOURNAL OF CONTROLLED RELEASE
- The Bcl-2/Bcl-XL/Bcl-w Inhibitor, Navitoclax, Enhances the Activity of Chemotherapeutic Agents In Vitro and In Vivo
- (2011) J. Chen et al. MOLECULAR CANCER THERAPEUTICS
- Cisplatin as an Anti-Tumor Drug: Cellular Mechanisms of Activity, Drug Resistance and Induced Side Effects
- (2011) Ana-Maria Florea et al. Cancers
- Intracellular targeting delivery of liposomal drugs to solid tumors based on EPR effects
- (2010) Kazuo Maruyama ADVANCED DRUG DELIVERY REVIEWS
- Treatment options for advanced endometrial carcinoma
- (2010) Don S. Dizon GYNECOLOGIC ONCOLOGY
- Bcl-2 Inhibitors: Targeting Mitochondrial Apoptotic Pathways in Cancer Therapy
- (2009) M. H. Kang et al. CLINICAL CANCER RESEARCH
- Nanoparticle-mediated simultaneous and targeted delivery of paclitaxel and tariquidar overcomes tumor drug resistance
- (2009) Yogesh Patil et al. JOURNAL OF CONTROLLED RELEASE
- A History of Cancer Chemotherapy
- (2008) Vincent T. DeVita et al. CANCER RESEARCH
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More